ClinicalTrials.gg
Status unknownNCT04234594Updated May 19, 2020

Comparing the Pharmacokinetic and Safety of QL1203 and Vectibix® in Healthy Males.

A Phase 1 interventional study of QL1203 and Vectibix® in Healthy Males, sponsored by Qilu Pharmaceutical Co., Ltd.. Status unknown at 2 sites in China. Open to male participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-05-19.

Sponsored by Qilu Pharmaceutical Co., Ltd. · Phase 1, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Jan 2020), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
94
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
Male
01

Study summary

A randomized, double-blind and parallel group study to compare the pharmacokinetic and safety of QL1203 and Vectibix® in healthy males.

Read the detailed description

This is a phase I,single center, randomized, double-blind,single-dose and parallel group clinical trial . The primary objective is to assess the pharmacokinetic similarity of of QL1203 or Vectibix® in healthy male volunteers. The secondary objective are to assess the Clinical safety and immunogenicity similarity of QL1203 or Vectibix® in healthy male volunteers".

02

Conditions studied

  • Healthy Males
03

In context

Lead sponsor

Qilu Pharmaceutical Co., Ltd. is the lead sponsor of 200 studies on the registry; 122 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects sign the form and fully understand purpose, nature, process and possible adverse reactions of the study, and are able to complete the study according to the study plan requirements.
  • Male,18 years to 65 years of age.
  • Weight ≧50.0 kg; (BMI) in the range of 19.0~ 26.0 kg / m\^2.
  • Subjects have no history of chronic diseases or serious diseases such as cardiovascular, liver, kidney, respiratory, blood and lymph, endocrine, immune, psychiatric, nervous, gastrointestinal system diseases and the general health is good.
  • Clinical laboratory examination, chest X-ray, abdominal B-ultrasound, , physical examination, vital signs and various examinations are normal or abnormal without clinical significance.

Exclusion criteria

Exclusion Criteria:

  • Subjects have used any biological product within 3 months prior to receiving the study drug, or have used any monoclonal antibody drugs within 9 months.
  • Subjects have anallergic history to study drug or any drug component; or persons with allergic history to two or more drugs and food.
  • Subjects have a history of interstitial lung disease.
  • Subjects have a history of keratitis or long-term wearing of contact lens.
  • Subjects have used any prescription drugs, over-the-counter medicines, Chinese herbal medicines, and vitamins within 2 weeks before receiving the study drugs.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
94 participants (estimated)

Study arms

  • Experimental
    QL1203

    Participants only receive QL1203, 6mg/kg on Day 1.

    Drug: QL1203

  • Active comparator
    Vectibix®

    Participants only received Vectibix®,6 mg/kg on Day 1.

    Drug: Vectibix®

Interventions

  • DrugQL1203

    6 mg/kg intravenous (IV) infusion only once,on the first day.

  • 6 mg/kg intravenous (IV) infusion only once,on the first day.

06

What researchers measure

Primary outcomes

  1. Area under the plasma concentration-time curve (AUC0-t )

    Area under the plasma concentration-time curve (AUC0-t ) from 0 o'clock to the last measurable concentration acquisition time t.

    Time frame: 36 days

07

Study locations

2 of 2 sites recruiting
  • Guizhou Cancer Hospital
    Guiyang, Guizhou 550000, China
    Recruiting
    • Weiwei Ouyang, Professor · Contact
  • First Affiliated Hospital of Kunming Medical University
    Kunming, Yunnan 650032, China
    Recruiting
    • Hui Wu, Professor · Contact
    • Li He, Professor · Contact
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Oct 2019 (actual). Primary completion is estimated for Sep 2020, 11 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 16, 2020
First posted
Jan 21, 2020
StartActual
Oct 28, 2019
Primary completionEst.
Sep 30, 2020
CompletionEst.
Sep 30, 2020
Last update
May 19, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 19, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04234594
Responsible party
Sponsor
First posted
Jan 21, 2020
Start date
Oct 28, 2019
Primary completion
Sep 30, 2020 (estimated)
Completion
Sep 30, 2020 (estimated)
Last update
May 19, 2020

Study contacts

Shunjiang Yu, CMO
Contact
shunjiang.yu@qilu-pharma.com
0531-83129659
Weiwei Ouyang, Professor
principal investigator · Cancer Hospital of Guizhou Province

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jan 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: QL1203

Start the discussion